

## **Product datasheet for TA306546**

**LGI1** Rabbit Polyclonal Antibody

## **Product data:**

**Product Type:** Primary Antibodies

Applications: WB

Recommended Dilution: WB: 1 ug/mL

Reactivity: Human, Mouse, Rat

Host: Rabbit Isotype: IgG

Clonality: Polyclonal

**Immunogen:** LGI1 antibody was raised against a 13 amino acid peptide from near the amino terminus of

human LGI1.

**Formulation:** PBS containing 0.02% sodium azide.

**Concentration:** 1ug/ul

**Purification:** Affinity chromatography purified via peptide column

**Conjugation:** Unconjugated

**Storage:** Store at -20°C as received.

**Stability:** Stable for 12 months from date of receipt.

**Gene Name:** leucine-rich, glioma inactivated 1

Database Link: AAQ89244

Entrez Gene 9211 Human

<u>095970</u>

Background: The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor

suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist, but the top band seen in the western blot is likely to be non-specific. This LGI1 antibody

is predicted to be specific to LGI1 and not recognize other LGI proteins.



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn


Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



Synonyms:

ADLTE; ADPAEF; ADPEAF; EPITEMPIN; EPT; ETL1; IB1099

## **Product images:**



Western blot analysis of LGI1 in mouse brain tissue lysate with LGI1 antibody at 1 ug/ml in (A) the absence and (B) the presence of blocking peptide.